News & Events

XIDALI® Tadalafil Tablets Officially Launched! 36-Hour Long-Acting

2026-04-13
Therapy for ED Recently, XIDALI® Tadalafil Tablets (Approval No. H20255227) produced by Yangling Jitai Pharmaceutical Co., Ltd. has been approved and launched, providing a longer-acting, more conve...

Yangling Jitai Pharmaceutical Makes Debut at the 23rd China International Pharmaceutical Ingredients Expo, Driving Global Pharma Collaboration with Innovation

2026-03-31
From June 24 to 26, 2025, the 23rd China International Pharmaceutical Intermediates & Ingredients Expo (CPHI China 2025) grandly opened at the Shanghai New International Expo Center. As a pivotal p...

Twenty years of deep cultivation in medicine empowers global health

2026-03-31
In the current era of accelerated integration of the global health industry, a safe and compliant product system, full chain R&D and production capabilities, and an international service perspectiv...

Yangling Jitai Pharmaceutical Explores Asia-Pacific API Landscape at CPHI Japan, Forging New Cross-Border Pharma Partnerships

2026-09-16
Hosted at Tokyo Big Sight, CPHI Japan stands as a landmark gathering for pharmaceutical raw material stakeholders across the Asia-Pacific region. Bringing together API manufacturers, pharmaceutical...

Jitai Pharmaceutical Debuts at DUPHAT 2026 Dubai, Expanding Strategic Footprint Across the MENA Pharma Market

2026-10-09
Held at Dubai World Trade Centre from August 25 to 27, 2026, the 31st Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT 2026) stands as the most authoritative a...
1